Substances and New Organisms (HSNO) Act (Hazardous Substances and New Organisms 34 Act, 1996) . The EPA can regulate on the basis that an organism that has been treated with 35 dsRNA is a new organism, or instead categorize RNA as a chemical that could be a 36 hazardous substance. 37 RNA is not now and unlikely ever to be listed as a hazardous substance. This is deduced 38 from the observation that none of the terms RNA, dsRNA, ribonucleic acid, or siRNA return 39 anything in a search of the EPA's databases: "Approved hazardous substances with 40 controls", "Chemical Classification and Information Database", or "New Zealand Inventory 41 of Chemicals." Moreover, the Ministry of Primary Industries places RNA in the "Neglible 42
Risk Register" (MPI, 2018) . 43
Therefore if dsRNA-treated organisms are to be regulated at all, they must be under the 44 country's biosecurity laws * directed at pathogens and pests, or as new organisms by the 45 HSNO Act. A new organism may be in a species or sub-species new to New Zealand and/or 46 be a genetically modified organism of any species (full definition in Supplemental Material). 47
Here I analyze the routine case where an organism that is not new (or considered to be a 48 biosecurity threat) is treated with dsRNA, and whether that treatment results in the 49 organism being a new organism under the HSNO Act, by creating a genetically modified 50 organism. 51
The HSNO Act says that a "genetically modified organism means, unless expressly provided 52 otherwise by regulations, any organism in which any of the genes or other genetic 53 material-(a) have been modified by in vitro techniques; or (b) are inherited or otherwise 54 derived, through any number of replications, from any genes or other genetic material 55 which has been modified by in vitro techniques" (Hazardous Substances and New 56
Organisms Act, 1996) . 57
New Zealand is harmonized to the Cartagena Protocol on Biosafety (the Protocol) (CBD) 58 through its HSNO Act. The Protocol is an international treaty on the transboundary 59 movement of products of modern biotechnology, including living genetically modified 60 organisms. The Protocol does not apply to food and pharmaceutical products that are 61 unable to survive in the environment. The Protocol definition of a living modified organism 62 is "any living organism that possesses a novel combination of genetic material obtained 63 through the use of modern biotechnology." The Protocol definition of modern 64 biotechnology is "the application of: a. The nomenclature should be used as an indicative guide to biogenesis of the dsRNA, but not 131 the activity of the active form. This is because regardless of their source, dsRNAs share the 132 same pathways in the cell (Ghildiyal and Zamore, 2009 (Massirer and Pasquinelli, 2013) . The larger the number of 166 mismatches between the guide and target RNA, the more likely the silencing will be caused 167 by exonucleolytic decay or translational inhibition (Massirer and Pasquinelli, 2013 ways (Table S1 ) and different to the descriptions provided by either the applicant (Trought, 190 2018) or EPA staff (EPA, 2018b The Committee did not address the physical description of the dsRNA in the approved 226 treatments. The applicant sought permission to use "synthetic" dsRNA, restricted as well to 227 those that would cause a temporary effect on the "activity of the complementary RNA" 228 . Although siRNAs tend to get processed down to <30 nucleotides, the 229
Decision is not restricted to externally applied dsRNA molecules of <30 nucleotides. The 230 dsRNA molecules possibly could be further chemically modified to mimic other classes or 231
RNAs such as piRNAs (Ghildiyal and Zamore, 2009) Beyond modifications to the dsRNA molecules are the formulations or materials that might 236 be used to improve penetrance. The Decision imposed no restriction on method or material 237 for causing the dsRNA to be taken up by organisms. 238
The Decision makes it possible to use dsRNA made or amplified from natural sources, such 239 as cellular material, which could contain contaminating active RNA or retro viruses (Ngo et 240 al., 2017) . Without the requirement for the EPA to review any externally applied dsRNA, 241 treating a eukaryotic cell with either dsRNA corresponding to all or most of a messenger 242 RNA or most of an RNA virus genome would be allowed. Responsible use of dsRNA for 243 treating eukaryotes would unlikely include the purposeful amplification or modification of 244 RNA viruses. However, the Decision specifically removes EPA from responsibility for 245 protecting against inadvertent amplification of RNA viruses by saying "it was not necessary 246 to consider whether in vitro techniques were involved." This is surprising given the 247 accessibility of both genetic databases and recent revelations that a poxvirus was 248 assembled by purchasing the component DNA fragments through "the mail" and the 249 expectation that portable synthesizing equipment will be more common in the future 250 (Sharples, 2017 The type of patent used is a utility rather than plant variety patent and extends to the 266 ownership of organisms and future generations of organisms treated with exogenous 267 dsRNA similarly to how utility patents claim the use of genetically modified organisms. 268 "Several embodiments include a plant or a field of plants treated by a method, composition, 269 or apparatus described herein, wherein the plant exhibits a desirable phenotype (such as  270 improved yield, improved tolerance of biotic or abiotic stress, improved resistance to 271 disease, improved herbicide susceptibility, improved herbicide resistance, and modified 272 nutrient content) resulting from the treatment and when compared to an untreated plant. 273
Several embodiments include progeny seed or propagatable plant part of such plants, and 274 commodity products produced from such plants" (Huang et al., 2018) . 275
The maker of the dsRNA would apparently own an organism because it was exposed to the 276 dsRNA, potentially including entire fields of conventional crops or long-lived trees and their 277 seeds that have never been modified by insertion of DNA. 278 279
Exo-dsRNA Is Not Confined to the Cytoplasm 280 281
The Committee understood that exo-siRNA remains "solely as RNA molecules in the cell 282 cytoplasm outside the nucleus" (EPA, 2018a), consistent with advice received from staff 283 (paragraph 2.9 of Ref EPA, 2018b). Physical isolation of the genes and other genetic 284 material in the nucleus would be a biological barrier to inheritance of exo-dsRNA that was 285 confined to the cytoplasm (Fig. 1) . 286
However, no such barrier can be relied upon to keep dsRNA out of the nucleus. (Li, 2008) . In animals at least, the nuclear 316 envelope can also rupture, resulting in mixing of content (Hatch and Hetzer, 2014) . This 317 pathway is exploited by parvoviruses as part of the infection cycle. 318
319

Reverse transcription 320 321
Among potential barriers to inheritance is that exo-siRNAs will not be reverse transcribed 322 (Fig. 1) . Unfortunately, neither the Decision nor Staff Advice provided references or analysis 323
for the definitive existence of such a barrier. 324
Reverse transcriptase has the ability to synthesize a DNA molecule using an RNA molecule 325 as a co-factor (template), similar to how DNA itself replicates using a DNA strand as a co-326 factor in DNA replication. group for strand extension. The primer may come from the secondary structure (eg a 338 hairpin structure), as is common in precursors of siRNA. Alternatively, the primer is a 339 second molecule that binds to the template strand. The primer gives the reverse 340 transcriptase reaction specificity because it binds by complementarity to a target sequence. 341
At least in the laboratory, it is possible for a reverse transcriptase reaction to proceed 342 without the addition of any particular primer molecule because there are sufficient 343 numbers of small RNA molecules naturally present in the cytoplasm to serve this purpose 344 (Frech and Peterhans, 1994) . 345
It is uncertain whether all exo-dsRNA molecules could be substrates for reverse 346 transcriptase, but it is unlikely that none could be. RNA from viruses can be captured by 347 reverse transcriptase for conversion into DNA molecules and integration into chromosomal 348 DNA, as well as by Dicer for production of siRNA (Goic et al., 2013 The yeast and filamentous fungi are host to self-replicating dsRNA agents located in the 435 cytoplasm (Wickner, 1986) . These RNA elements range in size from 1.5 kilobase-pairs to 436 over 76 kbp. Moreover, these elements have acquired genes from other organisms and 437 other dsRNA elements through RNA-RNA recombination, making it possible for them to 438 acquire sequences directly from exo-dsRNAs (Ramírez et al., 2017 The limiting mechanisms are also not assurances that the transience of the effect is shorter 475 than ability of the effect to cause harm. Moreover, the limiting response can be reduced by 476 repeat exposures to the exo-dsRNA (Houri-Zeevi and Rechavi, 2017). Repeat exposures are 477 possible under the EPA Decision. According to the HSNO Act, an organism is modified when 478 its genes or other genetic material have been modified, not only when they are transmitted 479 to offspring. This is important to consider in particular for long-lived genetic resources or 480 other species of conservation value, such as trees. 481
Unintended Heritable Changes 482
The common biochemistry accessed by exo-dsRNA and endo-dsRNA creates competition 483 between them (Waldron, 2016). Traits made stable and heritable by endo-dsRNA may be 484 destabilized through competition with exo-dsRNA. If the outcome of the competition for 485
Argonaute or other proteins is an alternative heritable pattern of gene expression, then this 486 too is a heritable effect of treatment with exo-dsRNA. 487
Exposing the eukaryote C. elegans to exo-dsRNA downregulated the production of endo-488 dsRNAs that are necessary for the inheritance of endo-dsRNA effects (Houri-Ze'evi et al., 489 2016). This effect was not specific to the sequence of the genes controlled by particular 490 endo-dsRNA, but to production of proteins necessary for intergenerational transmission of 491
RNAi caused by endo-dsRNAs. 492
A critical feature of this observation is that any attempt to determine the longevity of exo-493 dsRNA-mediated RNAi must define how often an organism will be exposed to exo-dsRNA. 494 This is because the "'transgenerational timer' is being reset by initiation of new RNAi 495 responses, and therefore 'second triggers' extend the inheritance of ancestral silencing" 496 (Houri-Ze'evi et al., 2016). Exposure frequencies will determine the duration of the effect 497 both in time and number of generations. 498
499
Conclusion 500 501
The EPA Decision defines the use of dsRNA applied externally to eukaryotes as out of scope 502 of their legislation. The Decision has important implications because all native and 503 endogenous eukaryotes, even those yet to be discovered, as well as those described as 504 exotics, with the exception of organisms banned by biosecurity laws, come under the 505 jurisdiction of the HSNO Act. 506 A significant concern is that the Decision might extend to the unregulated use of RNA 507 genomes of viruses or modified viruses. The Committee: 508
• put no constraints on the size of the dsRNA molecules. 509
• constrained treatment to organisms that are not excluded by the Biosecurity Act, 510 but did not constrain the source of the dsRNA to be used. 511
• decided that in vitro techniques did not have to be considered, removing any 512 obligation to notify the use of in vitro conversion or synthesis of RNA genomes 513 into dsRNA molecules. 514
• did not describe what it meant by external treatments, leaving chemical and 515 biological vectors (eg ingestion of micelles) of any description possible. 516
Heritability 517
The EPA was certain that exo-dsRNA molecules could not be inherited by eukaryotes and 518 this was the primary rationale for the determination that eukaryotes treated with them 519
were not new or genetically modified organisms for the purposes of the HSNO Act. 520
Prohibiting inheritance were various biological barriers ( Fig. 1) : 521
• exo-dsRNA does not mix with material in the nucleus of the cell. This, however, was 522
shown to be false. Moreover, the EPA failed to account for replicating RNA elements 523 in the cytoplasm of some eukaryotes, and the literature on RNA-RNA recombination. 524
• exo-siRNA is not reverse transcribed. This was shown to be plausible for some 525 dsRNA molecules but demonstrably false for others. 526
• exo-dsRNA is not inheritable because it does not modify the DNA genome. This was 527
shown to be false. First, exo-dsRNA may replicate independently of the DNA genome 528 using RdRP-based amplification, as can other RNA-based elements in eukaryotes 529 that are clearly genetic material. Second, exo-dsRNAs can modify DNA in 530 chromosomes in some cell types or species. Modifications include heritable 531 methylation of nucleotides and histones, DNA deletions and rearrangements, and 532 changes in chromosome copy number. 533
In contrast to the EPA, the industry developing dsRNA treatments for broad scale 534 environmental applications is convinced that the treatments result in heritable changes. For 535 example, an exo-dsRNA treatment was used to effect a color change in petunia flowers that 536 resulted in subsequent generations of the plant that retained the modified trait. Those 537 progeny were used to illustrate the multi-generational claim of ownership made by the 538 patent holder (see paragraph 0173 of Ref. Huang et al., 2018) . 539
Terminology 540
The common understandings of terms not already defined in the HSNO Act served in this 541 instance to reinforce the conclusion that dsRNA did not modify genes or other genetic 542 material (EPA, 2018b These are also of practical value because they underpin international rules of trade and 551 protection of organisms and biological material. In carefully negotiated and legally binding 552 international instruments, it can be as deliberate to choose to not define particular terms as 553 it is to define others. In the agreements described earlier, genetic material is not defined as 554 specifically and exclusively the DNA of chromosomes in the nucleus of cells. Using the 555 definitions from those instruments, modification of genetic material can result from 556 changing the DNA of chromosomes in the nucleus, but also in other ways, such as by 557 changing the replicating RNA elements in the cytoplasm of cells that have these, or the 558 histone proteins of chromosomes in cells that will pass on an associated trait. 559
In Decision paragraph 4.9 the Committee said that it required evidence of dsRNA 560 integrating into the genome (ie, according to Decision paragraph 4.6, to be chemically 561 attached to the DNA of chromosomes in the nucleus), or the dsRNA itself had to in some 562 other way become inheritable, for the conclusion to be reevaluated. Implicit in the Decision 563 text was that the modification had to be the continued propagation of the dsRNA, rather 564 than the changes it made to the genetic material of an organism. Certainly if the dsRNA 565 were propagated that would satisfy international definitions of modification, which also can 566 mean a change to the primary order of nucleotides in a DNA molecule as would result from 567 linkage to a dsRNA molecule, if that could occur. However, the terms used by international 568 instruments are also consistent with what agencies such as the UN Food and Agriculture 569
Organization include, such as the "chemical modifications of DNA and chromatin, for 570 instance, affecting the degree of chromatin compaction or the accessibility of regulatory 571 sequences to transcription factors" (emphasis added to Ref CGRFA, 2015) . As discussed 572 above, that is a kind of modification that can result from a treatment with exo-dsRNAs 573 without reliance on continued transcription (Rechavi, 2014 Likewise, EPA could have reduced compliance costs for those using exo-dsRNA in contained 596 facilities by limiting the approval to synthetically produced dsRNA molecules, as requested 597 in the original application, prohibiting dsRNA derived from pathogens such as RNA viruses. 598
Work using dsRNA derived from viruses would then require additional risk assessment. 599
It is important to emphasize that RNA effects are still rapidly being described even in model 600 research organisms. "Among some animal groups [in New Zealand], new species are being 601 discovered faster than scientists can cope with them" (Various) much less test them for 602 dsRNA responses. The clear statements that there is likely to be much more to discover 603 about dsRNA effects as more species are studied, statements made in the references used to 604 develop advice from staff (EPA, 2018b), were not mentioned in the advice provided to the 605
Committee. The narrow treatment by EPA of how dsRNA could modify genes or genetic 606 material is surprising given the nation's pride in its native biodiversity. 607
Biosafety risk assessment is a technical specialty wherein the complexity of the biological 608 world must be fully considered and uncertainty in the extent of our knowledge humbly 609 recognized. In the future, it might be determined that some or all uses of externally applied 610 dsRNA create no unmanageable risks to human health, the environment, or to society. This 611 would be a welcome finding because there is potential for dsRNA-based products to be at 612 least short-term remedies for some problems. Coming to this position hopefully will be an 613 evidence-based and precautionary process. Only that kind of process has the ability to build 614 trust in responsible providers of biotechnology and agencies that serve to protect the 615 public's interest in the environment. Taking shortcuts will inevitably create delays. 616 
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